Hoth Therapeutics adds Miami site to expand HT-001 Phase 2a CLEER-001 trial enrollment

Reuters05:22

<a href="https://laohu8.com/S/HOTH">Hoth Therapeutics</a> adds Miami site to expand HT-001 Phase 2a CLEER-001 trial enrollment

Hoth Therapeutics Inc. announced an expansion of its CLEER-001 Phase 2a clinical trial of HT-001, adding Regis Clinical Research in Miami, Florida as a new enrolling site to increase enrollment capacity. HT-001 is being studied for skin toxicities associated with EGFR inhibitor cancer therapy, for which the company noted there is no FDA-approved treatment option. The company reported interim trial data showing patients in the open-label cohort met the primary efficacy endpoint (ARIGA rash severity score of 1 or less) by week six, with no dose reductions or discontinuations of EGFR inhibitor therapy while on HT-001 and no dose-limiting toxicities observed to date; it also referenced a case study presented at the American Academy of Dermatology Annual Meeting showing complete lesion and symptom resolution after one week of twice-daily application. The announcement did not specify when a full trial readout will be presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602241615PR_NEWS_USPR_____NY94862) on February 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614723398?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 05:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614723398","market":"nz","top_or_hot":-1,"title":"Hoth Therapeutics adds Miami site to expand HT-001 Phase 2a CLEER-001 trial enrollment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> adds Miami site to expand HT-001 Phase 2a CLEER-001 trial enrollment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced an expansion of its CLEER-001 Phase 2a clinical trial of HT-001, adding Regis Clinical Research in Miami, Florida as a new enrolling site to increase enrollment capacity. HT-001 is being studied for skin toxicities associated with EGFR inhibitor cancer therapy, for which the company noted there is no FDA-approved treatment option. The company reported interim trial data showing patients in the open-label cohort met the primary efficacy endpoint (ARIGA rash severity score of 1 or less) by week six, with no dose reductions or discontinuations of EGFR inhibitor therapy while on HT-001 and no dose-limiting toxicities observed to date; it also referenced a case study presented at the American Academy of Dermatology Annual Meeting showing complete lesion and symptom resolution after one week of twice-daily application. The announcement did not specify when a full trial readout will be presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602241615PR_NEWS_USPR_____NY94862) on February 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Therapeutics adds Miami site to expand HT-001 Phase 2a CLEER-001 trial enrollment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Therapeutics adds Miami site to expand HT-001 Phase 2a CLEER-001 trial enrollment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-25 05:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> adds Miami site to expand HT-001 Phase 2a CLEER-001 trial enrollment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced an expansion of its CLEER-001 Phase 2a clinical trial of HT-001, adding Regis Clinical Research in Miami, Florida as a new enrolling site to increase enrollment capacity. HT-001 is being studied for skin toxicities associated with EGFR inhibitor cancer therapy, for which the company noted there is no FDA-approved treatment option. The company reported interim trial data showing patients in the open-label cohort met the primary efficacy endpoint (ARIGA rash severity score of 1 or less) by week six, with no dose reductions or discontinuations of EGFR inhibitor therapy while on HT-001 and no dose-limiting toxicities observed to date; it also referenced a case study presented at the American Academy of Dermatology Annual Meeting showing complete lesion and symptom resolution after one week of twice-daily application. The announcement did not specify when a full trial readout will be presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602241615PR_NEWS_USPR_____NY94862) on February 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL8rmpJw:1","article_id":"2614723398","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614723398","pubTimestamp":1771968172,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hoth Therapeutics Inc. announced an expansion of its CLEER-001 Phase 2a clinical trial of HT-001, adding Regis Clinical Research in Miami, Florida as a new enrolling site to increase enrollment capacity. HT-001 is being studied for skin toxicities associated with EGFR inhibitor cancer therapy, for which the company noted there is no FDA-approved treatment option. The company reported interim trial data showing patients in the open-label cohort met the primary efficacy endpoint  by week six, with no dose reductions or discontinuations of EGFR inhibitor therapy while on HT-001 and no dose-limiting toxicities observed to date; it also referenced a case study presented at the American Academy of Dermatology Annual Meeting showing complete lesion and symptom resolution after one week of twice-daily application. The announcement did not specify when a full trial readout will be presented.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","HOTH":"Hoth Therapeutics"},"translate_title":"Hoth Therapeutics增加迈阿密站点以扩大HT-001 2a期CLEER-001试验招募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":0.9},"content_text":"Hoth Therapeutics adds Miami site to expand HT-001 Phase 2a CLEER-001 trial enrollment\n    \n\n        Hoth Therapeutics Inc. announced an expansion of its CLEER-001 Phase 2a clinical trial of HT-001, adding Regis Clinical Research in Miami, Florida as a new enrolling site to increase enrollment capacity. HT-001 is being studied for skin toxicities associated with EGFR inhibitor cancer therapy, for which the company noted there is no FDA-approved treatment option. The company reported interim trial data showing patients in the open-label cohort met the primary efficacy endpoint (ARIGA rash severity score of 1 or less) by week six, with no dose reductions or discontinuations of EGFR inhibitor therapy while on HT-001 and no dose-limiting toxicities observed to date; it also referenced a case study presented at the American Academy of Dermatology Annual Meeting showing complete lesion and symptom resolution after one week of twice-daily application. The announcement did not specify when a full trial readout will be presented.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602241615PR_NEWS_USPR_____NY94862) on February 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614723398","isCrawlerRequest":true}